Michelle M. O’Shaughnessy

Author

Also Known As

Helmuth, Margaret E., Kopp, Jeffrey, M O'Shaughnessy, M OʼShaughnessy, M O’Shaughnessy, M. M. O'Shaughnessy, M. O'SHAUGHNESSY, M. O'Shaughnessy, M. O’SHAUGHNESSY, M. O’Shaughnessy

132

Publications

4.1K

Citations

H-Index

Concepts

All Affiliations

Stanford University University of North Carolina at Chapel Hill University of Michigan Emory University Arbor Research Collaborative for Health

About

Michelle M. O’Shaughnessy is an author at Stanford University specializing in medicine, chronic kidney disease, and surgery.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	11	12	723
2	Public Health	3	3	100
3	Engineering	1	1	21
4	Health Sciences	1	1	21
5	Applied Physiology	1	1	21

Michelle M. O’Shaughnessy

Publications

3.6K

Citations

H-Index

Page 1

	Year	Citations
Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a “Kidney Disease: Improving Global Outcomes” (KDIGO) Controversies Conference Timothy H.J. Goodship, H. Terence Cook, Fádi Fakhouri, Kidney International	2016	674
Management and treatment of glomerular diseases (part 1): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference Jürgen Floege, Sean Barbour, Daniel Cattran, Kidney International	2019	257
C3 Glomerulopathy Nicholas Medjeral‐Thomas, Michelle M. O’Shaughnessy, John O’Regan, Clinical Journal of the American Society of Nephrology	2013	243
Glomerular disease frequencies by race, sex and region: results from the International Kidney Biopsy Survey Michelle M. O’Shaughnessy, Susan L. Hogan, Bawana D. Thompson, Nephrology Dialysis Transplantation	2017	228
Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial Brad H. Rovin, Jonathan Barratt, Hiddo J.L. Heerspink, The Lancet	2023	224
Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial Hiddo J.L. Heerspink, Jai Radhakrishnan, Charles E. Alpers, The Lancet GlomerulonephritisActive-controlled Clinical TrialRenal FunctionKidney FailureChronic Kidney Disease	2023	203
Management and treatment of glomerular diseases (part 2): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference Brad H. Rovin, Dawn J. Caster, Daniel C. Cattran, Kidney International	2019	181
Recurrence of FSGS after Kidney Transplantation in Adults Audrey Uffing, María José Pérez‐Sáez, Marilda Mazzali, Clinical Journal of the American Society of Nephrology	2020	173
Temporal and Demographic Trends in Glomerular Disease Epidemiology in the Southeastern United States, 1986–2015 Michelle M. O’Shaughnessy, Susan L. Hogan, Caroline J. Poulton, Clinical Journal of the American Society of Nephrology	2017	145
CureGN Study Rationale, Design, and Methods: Establishing a Large Prospective Observational Study of Glomerular Disease Laura Mariani, Andrew S. Bomback, Pietro A. Canetta, American Journal of Kidney Diseases Glomerular DiseaseGlomerulonephritisHemodialysisRenal FunctionRenal Disease	2018	131

Page 1